35+ Companies are Working to Improve the Opioid Dependence Treatment Space | Major Companies- Medicenna Therapeutics, Tarveda Therapeutics, and others

DelveInsight's, "Opioid Dependence Pipeline Insight 2023," report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Opioid Dependence pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Opioid Dependence Pipeline Report

• DelveInsight's opioid dependence pipeline report depicts a robust space with 25+ active players working to develop 28+ pipeline therapies for opioid dependence treatment.

• The leading opioid dependence companies include Sen Jam Pharmaceutical, Mindmed, Emergent BioSolutions, Opiant Pharmaceuticals, ATAI Life Sciences, Aphios, Inventage Lab Inc., Trevena Inc., Foresee Pharmaceuticals Co., Ltd, DemeRx, AphioTx Inc., Lyndra Therapeutics, AstraZeneca, Orexo AB, Alar Pharmaceuticals, Ensysce biosciences, Gilgamesh Pharmaceuticals, Indivior, Cerevel Therapeutics, BioCorRx, Kinoxis Therapeutics, Aptinyx, and others

• Promising opioid dependence pipeline therapies include SJP 006, SJP 007, Zolunicant, Naloxone multidose nasal spray, Intranasal nalmefene, Morphine extended release, KUR 101, C4X 3256, APH-1501, IVL3004, TRV734, DMX-1002, FP-004, DMX-NB1, DMX-IB1, LYN-014, LYN-013, AZD4041, OX124, OX125, ALA-1000, ALA-1300, ALA-2000, GM-300X, SBS-226, CVL-354, BICX104, KNX100, NYX-783, and others.

• The Opioid Dependence Companies and academics are working to assess challenges and seek opportunities that could influence R&D Opioid Dependence. The therapies under development are focused on novel approaches to treat/improve Opioid Dependence.

Request a sample and discover the recent advances in Opioid Dependence Drug Treatment @ Opioid Dependence Pipeline Report- https://www.delveinsight.com/sample-request/opioid-dependence-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Opioid Dependence Overview
Opioid use disorder is the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorders affect over 16 million people worldwide, over 2.1 million in the United States, and there are over 120,000 deaths worldwide annually attributed to opioids. There are as many patients using opioids regularly as there are patients diagnosed with obsessive-compulsive disorder, psoriatic arthritis, and epilepsy in the United States.

Recent Developmental Activities in the Opiod Dependence Treatment Landscape

• In December 2022, the US Food and Drug Administration (FDA) accepted the resubmitted New Drug Application (NDA) for Brixadi (buprenorphine) extended-release weekly and monthly subcutaneous injection for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.

• Through a collaboration with the National Institute on Drug Abuse (NIDA), Trevena is developing TRV734 for use in medication-assisted therapy for the treatment of opioid use disorder. Similar to current standard treatment options, it targets the mu receptor, but with an optimized mechanism of action that preferentially engages the signaling pathway responsible for therapeutic effect, with reduced activation of the signaling pathway responsible for mu receptor-mediated adverse effects.

• LYN-014, Lyndra's investigational oral, ultra-long-acting extended-release weekly levomethadone capsule, is being developed for the treatment of people living with opioid use disorder (OUD). The capsule is expected to achieve this through a novel design that will provide extended gastric residence, controlled, steady drug release and timely passage into the gastrointestinal tract. In July 2021, LYN-014 received Fast Track designation (FTD) from the US Food and Drug Administration (FDA).

• In November 2022, Aptinyx Inc. announced the finalization of a grant, issued to researchers at Yale University School of Medicine, funding the research and development of NYX-783 for the treatment of OUD. The $5.6 million grant was awarded under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative, administered by the National Institute on Drug Abuse (NIDA). The first clinical study funded by the grant will be a randomized, double-blind, placebo-controlled, Phase I drug-drug interaction study to assess the safety, tolerability, and pharmacokinetics of NYX-783 in combination with oxycodone in individuals who use opioids.

Find out more information of the latest Drugs Launch, News, and Breakthroughs of the Opioid Dependence Pipeline Report @ Latest Opioid Dependence Drugs Launch- https://www.delveinsight.com/sample-request/opioid-dependence-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Opioid Dependence Emerging Drugs Profile

• Zolunicant: MindMed
Zolunicant (MM-110) is a α3β4 nicotinic cholinergic receptor antagonist that offers a novel mechanism to address a critical gap in current opioid use disorder treatment. Positive safety and tolerability results support the advancement of MM-110 and guide the Phase IIa dose design in individuals undergoing supervised opioid withdrawal. Phase IIa trial remains on track to initiate in Q2 2022.

• KUR-101: ATAI Life Sciences
KUR-101, is a derivative of mitragynine, the major active alkaloid of the kratom plant. KUR-101 is atypical opioid receptor modulators, boasting unique pharmacology that may make them safer than currently available opioids in treating pain.

Opioid Dependence Pipeline Therapeutics Assessment
There are approx. 35+ key companies which are developing the therapies Opioid Dependence. The companies which have their Opioid Dependence drug candidates in the most advanced stage, i.e phase III include Opiant Pharmaceuticals.

Learn more about the emerging Opioid Dependence pipeline therapies @ Opioid Dependence Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/opioid-dependence-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Opioid Dependence Pipeline Report

• Coverage- Global

• Opioid Dependence Companies- Sen Jam Pharmaceutical, Mindmed, Emergent BioSolutions, Opiant Pharmaceuticals, ATAI Life Sciences, Aphios, Inventage Lab Inc., Trevena Inc., Foresee Pharmaceuticals Co., Ltd, DemeRx, AphioTx Inc., Lyndra Therapeutics, AstraZeneca, Orexo AB, Alar Pharmaceuticals, Ensysce biosciences, Gilgamesh Pharmaceuticals, Indivior, Cerevel Therapeutics, BioCorRx, Kinoxis Therapeutics, Aptinyx, and others

• Opioid Dependence Pipeline Therapies- SJP 006, SJP 007, Zolunicant, Naloxone multidose nasal spray, Intranasal nalmefene, Morphine extended release, KUR 101, C4X 3256, APH-1501, IVL3004, TRV734, DMX-1002, FP-004, DMX-NB1, DMX-IB1, LYN-014, LYN-013, AZD4041, OX124, OX125, ALA-1000, ALA-1300, ALA-2000, GM-300X, SBS-226, CVL-354, BICX104, KNX100, NYX-783, and others.

• Opioid Dependence Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Opioid Dependence Market Drivers and Opioid Dependence Market Barriers, click here @ Opioid Dependence Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/opioid-dependence-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Opioid Dependence: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Opioid Dependence- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Intranasal nalmefene: Opiant Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Zolunicant: Mindmed
15. Drug profiles in the detailed report…..
16. Early Stage Products (Preclinical)
17. Sen Jam Pharmaceutical: SJP 007
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Opioid Dependence Key Companies
21. Opioid Dependence Key Products
22. Opioid Dependence- Unmet Needs
23. Opioid Dependence- Market Drivers and Barriers
24. Opioid Dependence- Future Perspectives and Conclusion
25. Opioid Dependence Analyst Views
26. Opioid Dependence Key Companies
27. Appendix

Got Queries? Find out the related information on Opioid Dependence Mergers and acquisitions, Opioid Dependence Licensing Activities @ Opioid Dependence Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/opioid-dependence-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.